Conv. Plasma
Nigella Sativa
Peg.. Lambda

All convalescent plasma..
Meta analysis
Home COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 37% Improvement Relative Risk Mortality, day 21 14% Recovery 16% primary Conv. Plasma  CAPSID  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 105 patients in Germany (August - December 2020) Lower mortality (p=0.19) and improved recovery (p=0.32), not sig. Körper et al., J. Clinical Investigation, Oct 2021 Favors conv. plasma Favors control

Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19

Körper et al., Journal of Clinical Investigation, doi:10.1172/JCI152264, CAPSID, NCT04433910
Oct 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 105 hospitalized patients in Germany, 53 treated with convalescent plasma, showing no significant difference in mortality or the primary composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21.
risk of death, 36.5% lower, RR 0.63, p = 0.19, treatment 11 of 53 (20.8%), control 17 of 52 (32.7%), NNT 8.4, day 60.
risk of death, 14.2% lower, RR 0.86, p = 0.79, treatment 7 of 53 (13.2%), control 8 of 52 (15.4%), NNT 46, day 21.
risk of no recovery, 15.9% lower, RR 0.84, p = 0.32, treatment 30 of 53 (56.6%), control 35 of 52 (67.3%), NNT 9.3, composite outcome of survival and no longer fulfilling criteria for severe COVID-19, day 21, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Körper et al., 15 Oct 2021, Randomized Controlled Trial, Germany, peer-reviewed, median age 60.0, 27 authors, study period 30 August, 2020 - 24 December, 2020, trial NCT04433910 (history) (CAPSID).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
The Journal of Clinical Investigation
C L I N I C A L M E D I C I N E, Sixten Körper, Manfred Weiss, Daniel Zickler, Thomas Wiesmann, Kai Zacharowski, Victor M Corman, Beate Grüner, Lucas Ernst, Peter Spieth, Philipp M Lepper, Martin Bentz, Sebastian Zinn, Gregor Paul, Johannes Kalbhenn, Matthias M Dollinger, Peter Rosenberger, Thomas Kirschning, Thomas Thiele, Thomas Appl, Benjamin Mayer, Michael Schmidt, Christian Drosten, Hinnerk Wulf, Jan Matthias Kruse, Bettina Jungwirth, Erhard Seifried, Hubert Schrezenmeier
BACKGROUND. COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment. METHODS. Patients (n = 105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. The primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21. RESULTS. The primary outcome occurred in 43.4% of patients in the CCP group and 32.7% in the control group (P = 0.32). The median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (P = 0.27). The median time to discharge from the hospital was 31 days in the CCP group and 51 days in the control group (P = 0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies, the primary outcome occurred in 56.0% of the patients (vs. 32.1%), with significantly shorter intervals to clinical improvement (20 vs. 66 days, P < 0.05) and to hospital discharge (21 vs. 51 days, P = 0.03) and better survival (day-60 probability of survival 91.6% vs. 68.1%, P = 0.02) in comparison with the control group. CONCLUSION. CCP added to standard treatment was not associated with a significant improvement in the primary and secondary outcomes. A predefined subgroup analysis showed a significant benefit of CCP among patients who received a larger amount of neutralizing antibodies. TRIAL REGISTRATION. NCT04433910.
Author contributions HS and SK wrote study protocol, coordinated the study, analyzed and interpreted data, and wrote the manuscript. HS, SK, and ES applied for funding. HS and ES were the lead investigators. MW, DZ, TW, KZ, BG, LE, PS, PML, MB, SZ, GP, JK, MMD, PR, TK, TT, HW, JMK, and BJ performed patient care and data collection. VMC and CD performed analysis of SARS-CoV-2 antibodies. MS performed SARS-CoV-2 PCR. TA managed the project. BM performed statistical analysis. All authors approved the manuscript.
Acosta-Ampudia, COVID-19 convalescent plasma composition and immunological effects in severe patients, J Autoimmun, doi:10.1016/j.jaut.2021.102598
Agarwal, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Alqahtani, Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease, Sci Rep, doi:10.1038/s41598-021-89444-5
Anand, Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset, Cell Rep Med, doi:10.1016/j.xcrm.2021.100290
Avendano-Sola, Convalescent plasma for COVID-19: a multicenter, randomized clinical trial, doi:10.1101/2020.08.26.20182444
Bajpai, Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial, doi:10.1101/2020.10.25.20219337
Balcells, Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, PLoS Med, doi:10.1371/journal.pmed.1003415
Bloch, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J Clin Invest, doi:10.1172/JCI138745
Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest, doi:10.1172/JCI138003
Estcourt, Roberts, Convalescent plasma for Covid-19, BMJ
Gharbharan, Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nat Commun, doi:10.1038/s41467-021-23469-2
Jahrsdorfer, Characterization of the SARS-CoV-2 neutralization potential of COVID-19-convalescent donors, J Immunol, doi:10.4049/jimmunol.2100036
Janiaud, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA, doi:10.1001/jama.2021.2747
Joyner, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med, doi:10.1056/NEJMoa2031893
Joyner, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.06.028
Klassen, The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis, Mayo Clin Proc, doi:10.1016/j.mayocp.2021.02.008
Kreye, A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model, Cell, doi:10.1016/j.cell.2020.09.049
Körper, Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies, Transfus Med Hemother, doi:10.1159/000515610
Li, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Libster, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med, doi:10.1056/NEJMoa2033700
Lim, Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis, Am J Respir Crit Care Med, doi:10.1164/rccm.202006-2405OC
Martin-Vicente, Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients, doi:10.1101/2021.03.08.21253121
Natarajan, Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma, mBio
O'donnell, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J Clin Invest, doi:10.1172/JCI150646
Piechotta, Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013600.pub2
Ray, open label randomised control trial, doi:10.1101/2020.11.25.20237883
Salazar, Significantly decreased mortality in a large cohort of Coronavirus Disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein IgG, Am J Pathol, doi:10.1016/j.ajpath.2020.10.008
Simonovich, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Winkler, Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection, Cell, doi:10.1016/j.cell.2021.02.026
Wouters, Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary, Vox Sang, doi:10.1111/vox.13060
Wölfel, Virological assessment of hospitalized cases of coronavirus disease 2019, Nature, doi:10.1038/s41586-020-2196-x
Zhou, Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and metaanalysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.07.029
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop